Navigation Links
Washing away painful wounds
Date:8/26/2009

More than six million people in the U.S. suffer from persistent wounds open sores that never seem to heal or, once apparently healed, return with a vengeance. The bedridden elderly and infirm are prone to painful and dangerous pressure ulcers, and diabetics are susceptible to wounds caused by a lack of blood flow to the extremities.

"The problem is chronic," says Prof. Amihay Freeman of Tel Aviv University's Department of Molecular Microbiology and Biotechnology. To solve it, he's developed a unique device that uses a solution to whisk away dead tissue, bathing the wound while keeping dangerous bacteria away.

Prof. Freeman's "Dermastream" provides an enzyme-based solution that flows continuously over the wound, offering an alternative treatment to combat a problem for which current treatments are costly and labor-intensive. It could save the American healthcare system millions of dollars a year, and could be in hospitals and doctor's offices soon: Dermastream has passed clinical trials in Israeli hospitals and may be available in the U.S. within the next year, says Prof. Freeman.

Smarter and less painful wound care

Employing a special solution developed at Prof. Freeman's Tel Aviv University laboratory, Dermastream offers a new approach to chronic wound care, a specialty known as "continuous streaming therapy."

"Our basic idea is simple," says Prof. Freeman. "We treat the wound by streaming a solution in a continuous manner. Traditional methods require wound scraping to remove necrotic tissue. That is expensive, painful and extremely uncomfortable to the patient. And while active ingredients applied with bandages on a wound may work for a couple of hours, after that the wound fights back. The bacteria build up again, creating a tedious and long battle."

Dermastream "flows" under a plastic cover that seals the wound, providing negative pressure that promotes faster healing. The active biological ingredient, delivered in a hypertonic medium, works to heal hard-to-shake chronic wounds. While traditional bandaging methods may take months to become fully effective, Dermastream can heal chronic wounds in weeks, Prof. Freeman says.

Liquid armor to fight bacteria

Dermastream is intended for use in hospitals, nursing homes, outpatient clinics and homecare. Prof. Freeman has founded a company that is currently collaborating with a Veterans Association hospital in Tucson, AZ, to bring the technology to the U.S. market.

Dermastream was an outgrowth of Prof. Freeman's original laboratory research, which investigated the use of enzymes for pharmaceutical applications. Enzymes were previously applied to wounds as ointments, but were slow-acting and required a great deal of time to apply. Coupling the enzymes with a continuous stream of liquid, he unlocked the power of the enzymes in a way that works and makes sense, he says.

"My solution helps doctors regain control of the chronic wound, making management more efficient, and vastly improving the quality of their patients' lives," Prof. Freeman concludes.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Related biology news :

1. Society for Prevention Research Meeting in Washington, D.C., May 27-29, 2009
2. Scientists discover hot spot for toxic HABS off Washington coastline
3. Hot spot for toxic harmful algal blooms discovered off Washington coast
4. Dog owners more likely to share germs with pets by not washing hands than by sleeping with dog
5. Research-based undergraduate course expands beyond Washington University
6. Washington University scientists first to sequence genome of cancer patient
7. Masks, hand washing, prevent spread of flu-like symptoms by up to 50 percent
8. TGen and Washington University researchers discover new approach to treating endometrial cancer
9. Analysis of Lake Washington microbes shows the power of metagenomic approaches
10. 5th Annual World Health Care Congress April 21-23, Washington, D.C.
11. Washington University unveils draft sequence of corn genome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Washing away painful wounds
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology: